Michael S. van der Veer
- Hematology top 1%
- Oncology top 5%
- Molecular Biology
- Immunology top 10%
- Radiology, Nuclear Medicine and Imaging top 5%
- Co-authors
- Michel de WeersJoost M. BakkerPaul W.H.I. ParrenTuna MutisTom VinkDaniëlle C.H. JacobsJan G. J. van de WinkelHenk M. Lokhorst
- Topics
- Multiple Myeloma Research and Treatments (6 papers)Monoclonal and Polyclonal Antibodies Research (3 papers)Chronic Lymphocytic Leukemia Research (3 papers)
- Cited by
- HematologyPhysiologyOncology
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
Michael S. van der Veer
7 papers receiving 992 citations
Hit Papers
Peers
Comparison fields: 5 of 51
- Hematology 731
- Oncology 528
- Molecular Biology 429
- Immunology 268
- Radiology, Nuclear Medicine and Imaging 246
Countries citing papers authored by Michael S. van der Veer
This map shows the geographic impact of Michael S. van der Veer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. van der Veer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. van der Veer more than expected).
Fields of papers citing papers by Michael S. van der Veer
This network shows the impact of papers produced by Michael S. van der Veer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. van der Veer. The network helps show where Michael S. van der Veer may publish in the future.
Co-authorship network of co-authors of Michael S. van der Veer
This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. van der Veer. A scholar is included among the top collaborators of Michael S. van der Veer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. van der Veer. Michael S. van der Veer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 81 | |
| 2 | 2 | |
| 3 | 168 | |
| 4 | 2 | |
| 5 | 1 | |
| 6 | Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumorsbreakdown → | 746 |
| 7 | Age-related negative associations between parameters of cytogenetic damage and ex vivo (+/-)-anti-benzo(a)pyrene diolepoxide-induced unscheduled DNA synthesis in smoking humans. | 4 |
About Michael S. van der Veer
Michael S. van der Veer is a scholar working on Hematology, Genetics and Oncology, having authored 7 papers that have together received 1.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (6 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Hematology (731 citations), Physiology (120 citations) and Oncology (528 citations). Michael S. van der Veer has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Michel de Weers, Joost M. Bakker, Paul W.H.I. Parren, Tuna Mutis, Tom Vink, Daniëlle C.H. Jacobs, Jan G. J. van de Winkel, Henk M. Lokhorst, Jerry W. Slootstra and Kenneth C. Anderson. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.